Carlos Ávila graduated in Biochemistry from the University of Seville in 2016, after one year of internship in the Centro Andaluz de Biología del Desarrollo. In 2017 he moved to Barcelona to undertake a MSc in Advanced Immunology from the University of Barcelona - Autonomous University of Barcelona. His MSC thesis, carried out in IrsiCaixa, was focused on the development of an ex vivo cellular model to evaluate shock and kill therapies in HIV patients.
In 2018 he worked in AlbaJuna Therapeutics, SL., a IrsiCaixa spin-off, as a lab technician involved in the production and purification of antibodies. Since 2019 he has been employed as a pre-doctoral researcher in the IrsiCaixa Cell Virology and Immunology group, with Dr Julià Blanco and Dr Jorge Carrillo as his thesis supervisors. His work is focused on the development of a syphilis vaccine based on virus-like particles (VLPs) derived from HIV.
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
Piglets inoculated by different routes are not susceptible to SARS-CoV-2, but those inoculated parenterally were immunized against the virus.
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.
Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes